Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

被引：0
|
作者：
Wataru Fukuokaya
Takahiro Kimura
Takafumi Yanagisawa
Shoji Kimura
Shunsuke Tsuzuki
Yuhei Koike
Yuya Iwamoto
Yuki Enei
Masatoshi Tanaka
Fumihiko Urabe
Hajime Onuma
Mariko Honda
Jun Miki
Yu Oyama
Hirokazu Abe
Shin Egawa
机构：
[1] The Jikei University School of Medicine,Department of Urology
[2] Kameda Medical Center,Department of Urology
[3] Kameda Medical Center,Department of Medical Oncology
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Urothelial carcinoma; Pembrolizumab; Programmed death-1; Immunotherapy; RECIST; iRECIST;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 236
页数：7
相关论文
共 50 条
  • [1] Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
    Fukuokaya, Wataru
    Kimura, Takahiro
    Yanagisawa, Takafumi
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Koike, Yuhei
    Iwamoto, Yuya
    Enei, Yuki
    Tanaka, Masatoshi
    Urabe, Fumihiko
    Onuma, Hajime
    Honda, Mariko
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Egawa, Shin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 229 - 236
  • [2] Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi, Satoru
    Kawai, Taketo
    Nakagawa, Tohru
    Kume, Haruki
    BJU INTERNATIONAL, 2024, 134 (01) : 43 - 44
  • [3] Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4519 - 4528
  • [4] Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma
    Hatano, Takashi
    Matsu-ura, Taishi
    Mori, Kei-ichiro
    Inaba, Hiroyuki
    Endo, Katsuhisa
    Tamari, Mayumi
    Egawa, Shin
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (05) : 473 - 476
  • [5] Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.
    Qin, Shukui
    Wen, Lu
    Wang, Junsheng
    Deng, Wenying
    Zhang, Guifang
    Jia, Tongfu
    Ba, Yi
    Zhong, Haijun
    Yang, Jianwei
    Lin, Xiaoyan
    Bai, Yu-Xian
    He, Yifu
    Xie, Zhong
    Yi, Tienan
    Wu, Xiangyuan
    Ye, Feng
    Liu, Likun
    Huang, Yong
    Wang, Mei
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
    Crist, Michael
    Iyer, Gopa
    Hsu, Miles
    Huang, William C.
    Balar, Arjun, V
    THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 9
  • [7] Virtual clinical trials: a tool for identifying patients who benefit from treatment beyond progression with pembrolizumab in NSCLC
    Qi, Timothy
    Cao, Yanguang
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (12)
  • [8] Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
    Nishimura, Nobutaka
    Miyake, Makito
    Shimizu, Takuto
    Tachibana, Akira
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    IJU CASE REPORTS, 2022, 5 (05) : 338 - 341
  • [9] Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma
    Wataru Fukuokaya
    Takafumi Yanagisawa
    Masaki Hashimoto
    Shutaro Yamamoto
    Yuhei Koike
    Yu Imai
    Kosuke Iwatani
    Hajime Onuma
    Kagenori Ito
    Fumihiko Urabe
    Shunsuke Tsuzuki
    Shoji Kimura
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Takahiro Kimura
    Cancer Immunology, Immunotherapy, 2023, 72 : 841 - 849
  • [10] Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
    Sekito, Takanori
    Bekku, Kensuke
    Katayama, Satoshi
    Watanabe, Tomofumi
    Tsuboi, Ichiro
    Yoshinaga, Kasumi
    Maruyama, Yuki
    Yamanoi, Tomoaki
    Kawada, Tatsushi
    Tominaga, Yusuke
    Sadahira, Takuya
    Iwata, Takehiro
    Nishimura, Shingo
    Kusumi, Norihiro
    Edamura, Kohei
    Kobayashi, Tomoko
    Kurose, Kyohei
    Ichikawa, Takaharu
    Miyaji, Yoshiyuki
    Wada, Koichiro
    Kobayashi, Yasuyuki
    Araki, Motoo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (04)
12345